Biodegradable Hemostat Market Size, Share and Global Trend By Product Type (Thrombin-Based Hemostat, Collagen Based Hemostat, Gelatin-Based Hemostat, Oxidized Regenerated Based Hemostat), By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers),Regional Forecast, 2024-2032

There is a gradual rise in the number of surgeries performed worldwide. Effective bleeding management during the surgeries in order to achieve haemostasis is one of the key determinants of positive outcomes. Difficulties in achieving haemostats are associated with excessive wound bleeding and requirement of blood transfusion especially in the case of anticoagulated patients.

The use of Biodegradable Haemostat increases haemostasis and also provides a wide range of benefits. The benefits of using biodegradable haemostat are reduced operative times, decrease the need for blood transfusion, better visualization of the surgical site and others. There are various existing and under research biodegradable agents which are used to establish haemostats. For example, LYDEX, a biomaterial made from dextran to be used for haemostasis in surgical procedures is under research by BMG Incorporated, a company focussed on developing biomaterial products. 

Increase in number of surgeries and rising concern for the prevention of surgical site or wounds from bleeding and infection are the primary reasons responsible for the growth in the global biodegradable hemostat market. In addition, the various potential advantages of using haemostat agents including the decreased requirement of transfusion, reduced wound healing time, reduced operative time and others are expected to further fuel the global biodegradable haemostat market during the forecast duration. 

However, the prominent use of sealants and adhesives to achieve haemostat as an alternative to biodegradable haemostat is a factor that is likely to hamper the growth in global biodegradable haemostat market. 

Key Players Covered 

Some of the major companies that are present in the global biodegradable haemostat market are Pfizer Inc., GELITA MEDICAL, Johnson & Johnson Services Inc., C. R. Bard Inc., Bristol-Myers Squibb Company, Stryker, Baxter, CryoLife Inc., Integra LifeSciences, and other players. 

  SEGMENTATION 

Among the end user, the hospital segment is estimated to have a greater market share in the global biodegradable hemostat market in the projected years, owing to the number of surgeries performed in the hospitals, usage in larger volumes and government guidelines for bleeding management.

Key Insights 

• Number of surgeries - for key countries
• Overview of upcoming biodegradable material for hemostat
• New product insights
• Pricing analysis
• Key mergers and acquisitions 

Regional Analysis 

The global biodegradable hemostat market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In North America, the biodegradable haemostat market is anticipated to register a fast growth in the forecast years due to the increased number of surgeries performed and active government interventions to avoid wound bleeding during surgeries. According to the Healthcare Cost and Utilization Project, in 2014, in the U.S., 17.2 million hospital visits (ambulatory or inpatient) included invasive, therapeutic surgeries, which is expected to boost the biodegradable haemostat market in North America. The biodegradable haemostat market in Europe and Asia Pacific is projected to expand by the end of 2025 owing to the rise in number of hospitals and improving health investments.

Key Industry Developments

• In May 2018, Cook Group, received the marketing approval for Hemospray, an endoscopic haemostat by FDA to prevent bleeding in gastrointestinal tract.
• In December 2018, Baxter introduced a disposable Curved Applicator, in order to improvised the delivery experience of the company’s biodegradable hemostat, Floseal Hemostatic Matrix product line for surgeries in the head & neck speciality, otolaryngology and, others
• BMG Incorporated, a company focussed on biomaterial products, is currently developing LYDEX, biomaterial made from dextran, to be used as substitute of fibrin glue, for haemostasis in surgical operations.